ResMed Inc. (RMD) Receives Consensus Rating of “Hold” from Analysts
ResMed Inc. (NYSE:RMD) has been given a consensus rating of “Hold” by the thirteen research firms that are currently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $65.83.
Several equities research analysts recently weighed in on RMD shares. Zacks Investment Research upgraded ResMed from a “hold” rating to a “buy” rating and set a $86.00 target price for the company in a report on Thursday, October 12th. BMO Capital Markets boosted their target price on ResMed from $70.00 to $74.00 and gave the stock a “market perform” rating in a report on Friday, October 27th. JPMorgan Chase & Co. boosted their target price on ResMed from $72.00 to $73.00 and gave the stock an “overweight” rating in a report on Monday, October 30th. Jefferies Group restated a “sell” rating and issued a $56.00 target price on shares of ResMed in a report on Thursday, October 12th. Finally, Northland Securities restated a “sell” rating and issued a $55.00 target price on shares of ResMed in a report on Friday, October 27th.
In other ResMed news, CFO Brett Sandercock sold 1,250 shares of ResMed stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $84.50, for a total value of $105,625.00. Following the transaction, the chief financial officer now directly owns 71,772 shares of the company’s stock, valued at approximately $6,064,734. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider David Pendarvis sold 6,364 shares of ResMed stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $82.20, for a total value of $523,120.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 158,929 shares of company stock worth $13,181,009. Company insiders own 1.77% of the company’s stock.
Shares of ResMed (RMD) traded up $0.74 during trading on Monday, hitting $87.78. The stock had a trading volume of 339,100 shares, compared to its average volume of 463,300. ResMed has a fifty-two week low of $62.64 and a fifty-two week high of $88.49. The company has a current ratio of 4.72, a quick ratio of 3.86 and a debt-to-equity ratio of 0.50. The firm has a market cap of $12,460.00, a price-to-earnings ratio of 35.54, a price-to-earnings-growth ratio of 2.22 and a beta of 0.78.
ResMed (NYSE:RMD) last posted its earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.66. ResMed had a return on equity of 21.53% and a net margin of 16.58%. The firm had revenue of $523.66 million during the quarter, compared to analyst estimates of $506.08 million. During the same period in the previous year, the company earned $0.62 EPS. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. equities research analysts predict that ResMed will post 3.04 EPS for the current year.
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.